Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment
Min Luo,Yan Lin,Rong Liang,Yongqiang Li,Lianying Ge
DOI: https://doi.org/10.2147/JIR.S324336
IF: 4.5
2021-08-28
Journal of Inflammation Research
Abstract:Min Luo, 1 Yan Lin, 1 Rong Liang, 1 Yongqiang Li, 1 Lianying Ge 2 1 Department of Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, People's Republic of China; 2 Department of Endoscopy, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, People's Republic of China Correspondence: Yongqiang Li Department of Oncology, Guangxi Medical University Cancer Hospital, Nanning, 530021, People's Republic of China Email Lianying Ge Department of Endoscopy, Guangxi Medical University Cancer Hospital, Nanning, 530021, People's Republic of China Email Background: The protein "human endogenous retrovirus H long terminal repeat-associating 2" (HHLA2), a member of the B7 family, has been linked to cancer progression and immune responses. However, its functional role in hepatocellular carcinoma (HCC) remains unknown. Methods: Bioinformatics was used to examine the potential roles of HHLA2 in HCC and the molecular pathways involved. Expression of HHLA2 and PD-L1 as well as the density of tumor-infiltrating lymphocytes (TILs) in tumoral areas were evaluated by immunohistochemistry and hematoxylin-eosin staining of 202 resected human HCC samples. Potential correlations of HHLA2 expression with pathological characteristics or prognosis of HCC patients were explored. Different types of immune microenvironment in HCC were defined based on HHLA2 expression and TIL density. Results: High HHLA2 levels in HCC correlated with more advanced clinical cancer stage ( P = 0.040), multiple tumors ( P = 0.044), poor tumor differentiation ( P = 0.048), microvascular invasion ( P = 0.011) and hepatic capsule invasion ( P = 0.047). HHLA2 levels correlated significantly with density of TILs, but not with PD-L1 levels. High HHLA2 levels were associated with worse prognosis. Intermediate and high TIL densities were independent predictors of better prognosis. Tumor microenvironments with type I (HHLA2 - high TILs +) or type IV (HHLA2 - low TILs +) were associated with better prognosis. Conclusion: HHLA2 level can independently predict worse prognosis and affect the tumor microenvironment in HCC, which may help guide immunotherapy against the cancer. Keywords: hepatocellular carcinoma, HHLA2, tumor-infiltrating lymphocyte, tumor microenvironment Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide and is considered a major cause of cancer-related death. 1 Most HCC cases are diagnosed at advanced stages, when prognosis is poor. Treatment options for advanced stages of HCC are often limited. The multi-target kinase inhibitor Sorafenib, as the standard first-line treatment, can enhance survival of patients with advanced HCC, but even so, median survival remains only 10.7 months and the drug is effective in only 2% of patients, yet it can trigger adverse events in as many as 80% of patients. 2 Immunotherapy has opened up new possibilities against HCC: antibodies against Programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1) act as immune checkpoint inhibitors and can achieve objective response rates of more than 20% and 30-month survival rates of 44%. 3 While levels of PD-L1 on tumor cells can predict prognosis and response to anti-PD-1/PD-L1 immunotherapy, not all patients with PD-L1-positive tumors respond to the treatment. 4–6 Another important factor may be the density of tumor-infiltrating lymphocytes (TILs), which, like PD-L1 levels in the tumor microenvironment, is associated with response to such therapy. 5,7 TILs are important components of the tumor microenvironment, which influences the progression of malignant tumors and the host's anti-tumor immune response. 8 In ovarian, breast, esophageal and colorectal cancers, TILs can inhibit tumor progression, affect the prognosis of patients, and predict the efficacy of tumor immunotherapy. 9–12 A retrospective study of 163 patients with HCC linked high numbers of TILs, mainly T cells, with lower rate of 5-year recurrence and longer overall survival (OS). 13 The protein "human endogenous retrovirus H long terminal repeat-associating 2" (HHLA2), a newly discovered member of the B7 family, co-stimulates and co-suppresses T cell proliferation and function, as well as the production of cytokines. 14,15 HHLA2 can also promote angiogenesis and promote tumor growth and metastasis. HHLA2 is highly expressed in various malignant tumor tissues, and it has been linked to tumor progression and metastasis. 16–22 In our preliminary study, we found that HHLA2 mRNA and protein levels were higher in HCC tissues than i -Abstract Truncated-
immunology